<DOC>
	<DOCNO>NCT01435291</DOCNO>
	<brief_summary>A pharmacokinetics pharmacogenetics study complement current knowledge tacrolimus prolong release ( Advagraf速 ) immediate post-transplantation period steady-state ( M3 post transplantation ) improve optimal dose Advagraf速 base tacrolimus AUC estimate two Limited Samples Strategies first 3 month renal transplantation . Data obtain tacrolimus prolonged release compare tacrolimus immediate release ( Prograf速 )</brief_summary>
	<brief_title>AADAPT - Analysis Advagraf Dose Adaptation Post Transplantation</brief_title>
	<detailed_description>Multicentre open-labeled randomize pharmacokinetic ( PK ) pharmacogenetic ( PG ) study compare Advagraf Prograf immediate post-transplantation ( Day 8 ) steady-state ( Day 84 ) systemic exposure . Tacrolimus PK profile , tacrolimus systemic exposure assess Limited Samples Strategies ( LSS ) ( i.e . : Bayesian estimator ( BE ) Multilinear Regressions ( MLR ) ) , impact CYP3A5 ABCB1 genetic polymorphism tacrolimus PK also determine improve optimal dose Advagraf速 kidney transplant patient .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<criteria>Adult recipient age 18 70 Primary renal transplantation Cadaver living transplantation living ( non HLA identical ) donor compatible ABO blood type . absence antiLHA antibody lymphocytotoxicity Luminex Negative crossmatch cytotoxicity Negative pregnancy test female patient childbearing potential , agreement practice effective birth control study Combined transplantation Renal bigraft History transplantation Receiving graft nonheartbeating donor . Requiring ongoing dose systemic immunosuppressive drug prior transplantation Patient receive within one month prior study inductor CYP50 3A require study inhibitor CYP50 3A Pgp . Significant , uncontrolled concomitant infection and/or severe diarrhoea , vomit , active upper gastrointestinal tract malabsorption active peptic ulcer Subject donor know HIV positive Active viral hepatitis ( VHB , VHC ) randomisation Known allergy intolerance tacrolimus , macrolide antibiotic , corticosteroid , mycophenolate mofetil product excipients Diagnosis newonset malignancy prior transplantation , exception basocellular squamous cell carcinoma skin treat successfully . Current participation clinical study Any clinical condition , opinion investigator , would allow safe completion study Patient able comply study procedure Breastfeeding mother</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>